The modified C2IIa could then be fused with polypeptides such as epidermal growth factor (EGF) or somatostatin, which promote the binding to EGF- or somatastatin-receptor that are frequently overexpressed on cancer cells [44], [45]. The gene discussed is SST; the disease is cancer.